<?xml version="1.0" encoding="UTF-8"?>
<p>A problem on which there has been extensive discussion on the use of DAAs was the cost of such therapies and this has led to give the indication to apply these treatments only to patients with extensive liver disease (F3 or F4). The high costs of the new drugs led to some prescriptive restrictions in the initial phase which unfortunately did not take into account the increase in the neoplastic risk linked to the iron accumulation for the transfusion dependent and hemolytic patients (Chung et al., 
 <xref rid="B7" ref-type="bibr">2015</xref>; Hodroj et al., 
 <xref rid="B12" ref-type="bibr">2019</xref>).
</p>
